Replay available

India Glycols (NSE:INDIAGLYCO) Q2 2027 Earnings Call

India Glycols (NSE:INDIAGLYCO) Q2 2027 earnings call, held 2026-11-18. Watch the replay and read the transcript on 6ix.

Wed, November 18, 2026 at 9:16 AMendedReplay
India Glycols (NSE:INDIAGLYCO) Q2 2027 Earnings Call
Company
India Glycols Limited (NSE:INDIAGLYCO)
Period
Q2 2027 earnings call
Date
Wed, Nov 18, 2026, 9:16 AM ET
Replay
Watch the replay on this page · 55 min

On 6ix: 6ix.com/event/india-glycols-limited-indiaglyco-q2-2027-earnings-call

Replay

Transcript

Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.

0:01 Ladies and gentlemen, good day, and welcome to India Glycols Limited Q2 and H1 FY 'twenty seven Earnings Conference Call. As a reminder, all participants will be in the listen only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Please note that this conference is being recorded. Today, from the management, we have with us Mr. Rupak Saraswat, Chief Executive Officer Mr. Anand Sagal, Chief Financial Officer Mr. Ankur Jain, Head Legal and Company Secretary. Before we begin, let me remind you that this discussion may contain forward looking statements that may involve known or unknown risks, uncertainties, and other factor.

0:56 It may be viewed in conjunction with the business risks that could cause future results, performance or achievements to differ significantly from what is expressed or implied by such forward looking statements. I now hand the conference over to Mr. Rupak Saraswat from India Glycols Limited. Thank you, and over to you, sir. So a very good afternoon to everybody for joining on this call. All of you are also in a way we had the unique privilege to do the first investor call in the name of a new India Glycols Limited, which is focused on chemical. And you are therefore also present in the first in the session meeting, which is very good. And I will take you through the results of this quarter, what we've done so far, broad highlights.

1:52 And since it is the first call after the demerger, we will also very briefly talk about the new structure and a little bit about the company, not too much because a lot of you already understand. Anandji will take you through the financials, and then we will take some questions. And I will also give you some input on the businesses, the overview, the operating environment, etcetera. So as you would have seen the results, we've had a strong growth momentum. So Q2 FY 'twenty seven for revenue has grown by 30% year on year to INR $3.58 crores, whereas for H1, the revenue increased 26% to INR $7.13 crores.

2:41 The margin growth for the have also been good. So EBITDA grew 26% year on year to 52 crores. Sorry, there was a somebody was telling me that the voice is not loud enough, so you were repositioning the mic. And 25% to 113 crores in H1 FY 'twenty seven. Now I will explain a little bit about what our broad classification of two reporting segments is. So our classification of reporting segments is bio based specialty materials. And then we have sustainable performance chemicals. I will explain also to you later on the rationale as to why we have classified some businesses in this.

3:35 But before coming to that, so specialty materials, largely which is driven by glycos and glycol has led the growth for ethylene revenue increased by 43% year on year to INR $3.82 crores. EBITDA is up 15% to INR 62 crores. For Performance Chemicals, Q2 revenue grew 36% to 167 crores and H1 revenue grew 29% to INR $3.13 crores, while EBITDA increased 49% from INR 24 crores in Q2 and 40% to INR 51 crores in H1. So margins expanded 13% to 14% in Q2 and from 15% to 16.3% in H1.

4:22 In the broadly, we've had an improvement in mix in bio based specialty materials, where revenue increased from 55% to 52%, supporting the shift towards the most specialty led portfolio. Now in terms of how we see the company going forward, I have spoken about it before. We would expect, as also was stated earlier, a lot of my statements would be directional, and I'm not going to make any prediction on outlook and numbers, even if we do speak about some numbers. The specialty materials will is expected to deliver steady growth. It has been a consistent business for us for the near term as well as for the longer term in the foreseeable future.

5:08 For the near term to midterm as well as the long term, Performance Chemicals will be an important pillar to drive growth, which is also happening this year. We will continue to see it this year as well as in the years to come. And by and large, our pipeline in that area is quite robust. We are also working on novel products and technologies, which is expected to drive significant growth in the mid- to longer term. In both the areas that I've spoken about, the new product pipeline, business development as well as working with diverse strategic partners is something which is quite robust and something that I'm satisfied and confident with. Now as you know, the demerger has been completed. So there are two business three businesses which have been listed now. One is Ideal Spirits Limited.

5:58 To refresh your memory, of course, Ideal Spirits Limited has portable spirits, which includes IMFL as well as country liquor. But it also now has the biofuels business as it's now. The whole idea was to leverage the synergy in ethanol, which can be manufactured together and which can service both the portable spirits business as well as the biofuels business. And Nature Biopharma business continues to be the business which had APIs as well as nutraceuticals as well as some branded products. But now it also has what was called the guar gum or the biopolymers business, which was generally spoken to along with the chemicals business. The rationale there is that biopolymers from a feedstock perspective is agro feedstock based. And also, there are several front end synergies, while it caters to oil and gas, etcetera, but also there is significant opportunity in biopolymers in the soluble fiber area, for example. So there is synergy in nutraceuticals. So that is reported there.

7:03 So as the India Glycols Limited or the chemicals business is concerned, it now has two big heads, which we will be reporting in. Within them, I will tell you what all is there. So one is what we call bio based specialty materials. You will say that both names look similar, so I will tell you they are not. Why we call them specialty materials and the other one performance chemicals? Now glycols and glycol ethers are materials which are sold on the basis of specifications, right? And these are specialty because they are unique. They are differentiated. They are bio based. As I said, we are perhaps only amongst a couple of people who make these products, which are bio based. And they also, especially glycols command a significant premium.

7:52 And of course, they are bio based. And as we start to manufacture more products in future, which may be from, say, carbon smart feedstock, so we'll probably graduate it from calling just bio based to sustainable. As far as Performance Chemicals is concerned, it has two big heads. One, it has the ethylene oxide we supply to the Clarion joint venture. And I will tell you why it has been put along with Performance Chemicals. And second, it has a new portfolio of new specialty chemicals that we are building, and that portfolio is doing very well, and that is growing. The reason ethylene oxide is also with Performance Chemicals is because that is exactly where it goes. It goes into personal care products, it goes into exercise products, crop care products, coatings products, lubricant products, which are specialty chemicals. And therefore, the drivers for this is are the drivers for Performance Chemicals.

8:47 And as far as our new Performance Chemicals portfolio is concerned, it will include a whole host of materials, fact that mines, etcetera, which I will speak subsequently. Gases, as I said, is a business very closely linked to manufacture of mono ethylene glycol because that is a raw material. So and it's a small business, depends on how much of glycols we are making. So we consume in house and as we sell. So we thought logically, it is better to cover it under that profit center together. So while we will continue to talk about the dynamics separately, that is how it will be. In terms of we would like to focus much more. We think that the future for Performance Chemicals and Green Chemicals is bright. Obviously, no bright future comes without challenges. So we will have to do many things, which will include building innovation, innovative products, introducing new functionalities, building on sustainability credentials.

9:47 And more importantly, something that we are focusing on is building strong partnerships and working for various end markets. So we do have a pure play focus. And we are amongst very few people who have a competence chain like this. So we manufacture the building blocks, and we are, in a sense, unique there, which is ethylene oxide, MBG, etcetera, starting obviously from ethanol. And then we go on to make several derivatives of them, some of which are semi commodity, commodity, etcetera. And then we also make specialty chemicals. Now the specialty chemicals bit is important because from our perspective, it is not about manufacturing the chemical. It is about delivering an effect in various performance areas. And we think we've got a strength across this value chain, which makes us kind of unique and something that we would like to leverage.

10:40 Along with that, my slide talks about deep process know how, global diversified reach, etcetera. But the broader thing is this allows us to position ourselves as good partners to people who are end consumers, for example, personal care companies or cost care companies, etcetera. But also equally importantly, to other people to whom we can be very good partners. There could be technology companies introducing green products. There could be B2C companies or performance or specialty companies like the BASF, Dow, etcetera, of the world, where we can bring certain unique strengths in manufacturing, green chemistry, etcetera, and to become very important partners of this. So that is the broad philosophy for IGL Chemicals to go forward.

11:31 And I have explained to you, therefore, bio based specialty materials, which will comprise glycols, monoethylene glycol, diethylene glycol, triethylene glycol, which will comprise glycol ethyl, glycol ethyl acetates going for various end applications, right, from packaging, textile, automotive, insulation, oil and gas, paint and coating, printing inks, perfumery, electronics, etcetera. There are some new segments that we may like to explore here. And then, of course, Performance Chemicals, which would be a wide range of chemistry platforms, which I will talk about in a bit and not spend more time on this slide. And other than that, what is also a part of this business in a sense is the joint venture with Clariant. So this now the joint venture with Clariant is of ideal.

12:19 We supply it to them. They make a wide range of performance and specialty chemicals, which to sell to various customers in India and abroad. Obviously, we don't compete in the segment. Ideal also makes products with you, but we have an agreement of where we will collaborate and where we will compete. So the end markets that we will cater to are quite diverse, as I mentioned. So right from packaging, textiles, oil and gas, coatings, personal care, agro, pharma, electronics, food and beverage, construction and polymers. Why is it important? Because if you look at all these end markets, for not only are they growing, all of them growing in the world, but particularly in a growing economy like India, they generally grow higher than GDP rates.

13:04 And so from an end market perspective, we are in areas which are growth areas, not only for the chemical industry, but particularly for India. And many of our platforms cater to many of these areas, whether it is glycols, glycolithers, performance chemicals or if I may say so, an extension of us, which is a joint venture, etcetera. Whilst something that we probably never talked about in investor calls, we are logistically advantaged. And I want to highlight it because contrary to what people might sometimes feel that we have factories in far away like Uttarakhand, especially if you are thinking of us sitting in Mumbai, if we are Lunabla is the favorite hill station. So it may feel like it is far away. But we have direct rail connectivity to our site, which is very interesting because if you have a site, which is 200,300 or 400 kilometers, say, within Gujarat or Maharashtra, compared to that a rail connectivity to the site with an on-site ICT makes the logistics safer, convenient as well as cost effective.

14:19 So particularly for exports or imports, if you see, we can access almost any significant port in the country, but the important ones on the western border for sure. Now I have also put in a slide, which is part of our introductory slide that we can look at various ways in which we source carbon, either biocarbon or subsequently circular feedstock. As you know, we have some work that we do with captured carbon, though it is not very significant in terms of business volumes. There are various foundational routes that we have. But we have significant strength in various derivatization platforms from epoxylation, epoxylation, epoxylation, phosphatation, etcetera.

15:05 There is a slide that I have put in. And we work on surface and interface, emulsification, demulsification, dispersion, etcetera, which do various things to various processes, right, from rheology modification to gelling and cross linking friction modification, etcetera. And these find applications in various end markets that we've talked about. So our journey apart from sustainable materials and producing them cost effectively and of high quality is to move to differentiated products, more importantly, to understand the application into and provide solutions and more importantly, to earn the confidence of our partners through collaborative projects where it is not about the transaction and even preferably become strategic partners based on sense of our company and there. And I'm happy to say that in many of our areas, in our pipeline, many of our projects are collaborative projects or strategic partnerships.

15:59 Now so that was how the company looks like in a slightly more focused manner after the demerger. Talking about coming to key financial highlights for Q2 and H1 'twenty seven. So revenue from operation in Q1 Q2 went up from two seventy six million to $358,000,000 which is up 30%. In H1, $5.68 to $713,000,000 which is up 26%. EBITDA from 42,000,000 to $52,000,000 in Q2, which is up 26%. 90% to 113% in net one, which is up 25% and a slight improvement in the EBITDA percent margin. So you see that the business performance has been robust, which we are happy with, but we also know there are lots of things which we need to do to continue to not only grow our business, but also improve the profitability.

16:54 In terms of the Specialty Materials business, the highlights, as I mentioned, are glycols and glycolysis. So glycol margins were under pressure interestingly because a number of the glycols that we sell to niche customers are exported. And there actually prices are linked to prices of U. S.-based imported ethanol. So whilst the crude prices went up and people thought MEG was in short supply and people will make more money in MEG, our prices in our margins were actually under pressure because prices were linked to ethanol. And at the same time, many of our costs went up. But I would only call it a spot issue as far as strategically the longer term business is concerned, it is fine and it will continue to deliver steady growth.

17:44 What it also did was provide us a small opportunity to sell some glycols in the domestic market. That was very small because we don't make much money there. As you know, crude based MEG is of a much lower cost. But because MEG prices went up with the volatility in crude, we were able to sell something. For glycol ethyl and acetate, it was some tailwind. So because crude based prices went up, so imports of glycol ethers into India became more expensive, not only glycol ethers, but other alternatives like butyl and propyl ethers. So we were able to sell much more volumes within India. We export a small volume, but not too much. So that was as far as the specialty materials business is concerned.

18:31 For Performance Chemicals, if you see sustainable and Performance Chemicals, revenue for Q2 was up from 123,000,000 to 167,000,000 which is up 36%. EBITDA in Q2 was 16,000,000 and in FY 'twenty seven sorry, 'twenty six was 16 FY 'twenty seven was 24, so up 49%. And there was some improvement in the EBITDA margin. So in terms of our Performance Chemicals, we've had I will talk about the macro environment and the operating environment a little bit. Our performance chemicals or the new performance chemicals had actually significant headwinds. Those significant headwinds were our oil and gas business, particularly where we sell materials and export materials to submit leads in other countries suffered quite badly.

19:20 Some of our raw materials like propylene oxide prices went up very high, which makes some of our products unviable and the volumes reduced. But we also had certain opportunities which came up. So all in all, actually, Performance Chemicals business has grown very well in terms of the top line. Nearly we may be nearly tripling our new Chemicals business in terms of top line this year with a healthy growth in overall margins as well, but percent margins have suffered. So there is a slide which talks about H1, but I think more or less covered. And so I will talk a little bit about the operating environment. And I have for your reference, I have a slide there. So what I've done is I've looked at the impact of Gaurf, Short Gulf supply, the rise of costs, etcetera.

20:14 So the impact on war essentially for us was two. One is the sharp volatility in crude prices and also supply disruptions from The Middle East, which affected us for manufacturing some of our products, but we also created some opportunity for some of our products like glycolithers. And I explained to you why whilst the crude prices are going up, our bio glycols margins shrank because of the correlation that we have and our contracts are based on bio based ethanol. So all in all, we had a slightly had a somewhat negative impact on glycols, a positive impact on glycol ethyls and acetates. And Performance Chemicals had a headwind, but reasonably happy to share that despite the headwind, the separate Performance Chemicals business actually in terms of top line is doing quite well.

21:07 So let me take a breather now to hand it over to Mr. Singhal, our CFO, to take you through the results and financials. Thank you, sir. So now about the Q2, just to tell you that since the last year, this company was on the consolidated entity, So results are not comparable. So I am comparing my results only Q2 versus Q1. So revenue from operations or revenue from operations in Q2 was $3.62 crores against INR $3.57 crores. The EBITDA in Q2 is INR 39 crore vis a vis Q1 crore 40 crore.

21:56 The EBITDA has reduced slightly because of the increase in the cost in the power fuel and some other expenses. The EBITDA margin in the current quarter means Q2 is 10.8% vis a vis 11.2% in the Q1. Activity is INR 28 crores vis a vis INR 37 crores. The difference is only because of the share of the JV, which has reduced to INR 13 crores vis vis INR 21 crores in Q1. And PAT is INR 24 crores vis a vis INR 33 crores in Q1. Relating to H1, the H1 'twenty seven was INR $7.20 crores, $7.20 crores, the revenue from operations with INR 2,133 crores in H1 last year, which, of course, is not comparable.

22:44 And the EBITDA margin in H1 is 11%, which is more or less in line with the Q1 and Q2. The VAT is INR 56 crores, the VAT margin is 7.8, showing an EPS of INR $8.40. So this is what is the H1. And this is what is the results from my side. Should we start the Q and A session, sir? Yes. There is though we since we had put this up in the on the website as well as we have discussed in some investor calls.

23:34 In terms of directionally, we see that there are three broad drivers for this business. One is sustainable specialty materials, which we think is regular is a regular business. We will continue to work on improving our cost position, differentiating our products, looking at new markets and new applications. Then there is sustainable and performance chemicals, which, as I mentioned, will be the growth engine from now onwards to the middle term to even the longer term, which includes a wide range of materials from surfactants, esters, quaternaries, polyglycerols, carbon smart materials are mined across a number of application areas, which I mentioned before. So this is a business that we are in the process of scaling up, where we have a strong new product business and development pipeline, which I'm quite confident about.

24:25 And then we have a significant role to play on several new technologies that we are working on, which includes captured carbon utilization of CO2, novel catalysis and new biotechnology based chemicals. And I'm talking about projects that either are ongoing in the lab or we are working in the pilot plant, and we have global collaborations, which we are working on. These are across multiple areas. Obviously, these are a little distant. There is a level of technology readiness level, as you say, involved in these projects, which is TRL. But I'm fairly confident of the direction and potential. And based on this, we have taken an aspiration that compared to the year, which has already gone, which is last financial year, we would scale up to becoming 10x in sales and ten years in EBITDA in ten years' time.

25:21 As I mentioned, the fundamentals are in place in terms of the market and the technologies that we are working on, and all of this needs doing. But to give ourselves a little bit conviction, not so much as to give a projection, this was the case. And we are aiming for about INR 2,000 crores revenue and about INR 400 crores EBITDA in the next four to five years. Since I put that slide this time, I thought I'll also talk about it. So that's all from my side, and over to you. Thank you very much, sir. We will now begin the question and answer Participants are requested to use handset while asking a question.

26:29 First question is from the line of Balasubramaniam from Aryan Capital. Please go ahead. Good evening, sir. Thank you so much for the opportunity. Sir, you have mentioned in H1 FY 'twenty seven, sustainable and performance chemicals margins have been improved. But if you look at in Page number 20, the PPT. But if you look at the same thing, next Page, 21, I think, mentioned about the operating environment, headwind is high, especially for performance chemicals. So how understand do whether it is related to sustainable and performance chemicals, whether it will impact in H2 on the margin side? And if you could clarify on the biopaste or specialty materials, almost 400 basis point impact is there?

27:25 So what you're saying is that as far as Performance Chemicals is concerned, you seem to be showing good growth, then why are you saying headwinds are right? Is that your question? Yes, sir. Okay. So see, there is sometimes you do well even in a bad operating environment also. So I'll tell you what it means. What it means is that we have, for example, a business, which is in oil and gas, which is in crop care, which is in personal care, etcetera, where we are putting up new capacities. So we have been able to get the business. And some business, we also did to get the top line because we were wanting to fill our assets. So we've done good on the top line, and we expect that our top line growth will be 2.5 to 3x maybe. But if you look at our percentage margins, they came down. And some of our fundamental businesses, which were, for example, in the oil and gas sector, which we wanted to do quite well.

28:31 We and some of our materials, used materials like propylene oxide, you see, I've also mentioned propylene oxide, lauryl alcohol, phenol, etcetera. The cost became very high. So it is correct that in the Performance Chemicals business and here, I am not talking about necessarily ethylene oxide to the joint venture. I'm talking about the new Performance Chemicals that we have introduced. Our operating environment in that sense was difficult. We actually lost or we several businesses slowed down and our profitability came down. But because we were scaling up the business, we did go after volume and we did do business at margins, which were relatively lower. So as the correction happens, going forward, what you will see what I would expect to see is I would see a toning down in terms of top line growth, but I would expect an enrichment of the margins.

29:26 So a number of these measures I would call to deal with this year were also tactical. After my next question, if you look at our major ethanol supply, now it's the backward integration of ethanol, it sticks with IGL spreads. But if you look at India Glycols in chemical business, earlier, we used to import, especially for chemical side. So how do you look at in coming years, whether we continue to import or is there any arrangement to like source from IGL spreads?

30:15 Okay. While these businesses are independently run at arm's length, but they we also recognize that there are synergies for all three businesses. The first synergy is the fact that we share a site and significant manufacturing infrastructure. The plants are definitely classified under ideal spirits. Now which means that on one hand, you may say that we are dependent as far as domestic supplies are concerned on our sister company, which is ideal spirits. On the other hand, you may say that across the border, they have a steady demand for their products. So this is something which is mutually beneficial.

31:01 Now as far as the choice of buying is concerned, the choice of doing the appropriate buying for this business is for with ideal chemicals, which means that if manufactured ethanol is more expensive and imported ethanol is cheaper, I can definitely buy and I will continue to buy imported ethanol. That is one part. The second thing is supposing ethanol costs become high become low in the Indian market because of excess capacity. And there are two possibilities. The portable spirit business supplies ethanol to biofuels as well as portable spirits. I have a choice of sourcing it from the source, which gives it to me in the best possible price. So as far as the risk to the business is concerned, it introduces no additional risk. In fact, there is right now significant ethanol supply in the country.

31:58 It continues to allow me to source from multiple places. But if we have to source from within India, the best place is to source it across the pipeline and not ship it across trucks, which is cost effective and value creating both for IGN spirits as well as for IGN chemicals. Sir, my last question, nearly 35% of sales are coming through exports. So if you could explain, is there any impact later to off rate and approval things? And secondly, how do you look at the mix change over next three to five years in terms of exports?

32:44 And what is the margin difference between domestic and export sales? So you are talking about the impact on exports because of rate increases? Yes, right. So freight has had as you see, if you look at my operating environment side as well, freight has had both kinds of impact, an adverse impact for materials that we export. Now as far as glycols are concerned, these prices are something that the customer pays and it builds it up. But what it does is it increases the cost to customers. And when it increases the cost to customer, the customer's ability to switch more to our products comes down, while it does not it gets built up in the price.

33:39 The second thing is where we are to seek new orders in exports, particularly where trade pent up very high, there we struggle to supply. There was also a small positive impact. The small positive impact was that if there were materials being supplied into India, say, from Middle East or somewhere for which we had alternatives like glycol So domestically, it became better for us. Now you've asked me a very interesting question, I wish I could answer, which is how does it look for the next four to five years? Everyday morning when I look at the television, the world seems to have changed. That is how volatile it is, especially given our friend, Mr. Trump.

34:28 So it is very difficult to predict for four to five years. But I'll tell you, the way to look at it in a more serious way is that, look, these kind of cyclical issues will come from time frame. And sometimes, it will appear that if you're unable to do business, your people have had the regional shutdown during Beijing Olympics and many romp deals became a crisis or when COVID happened. Or so many other things. I kind of doesn't necessarily agree with it. Remember the last one thousand years in India. I think we live in some of the most stable times. So coming to that, I think this volatility will continue. We are not in the business of creating opportunities out of spot opportunities. Some of them may be there. They are tactical issues.

35:15 Fundamentally, let us look at how I see the next four to five years from the chemical industries perspective. India is a growing market, fast growing market and will continue to remain a fast growing market for the next ten years. You agree, I agree. And when there is increase in income, the first thing that people spend is on discretionary spend. You've all got your rations taken care of, so people will spend more on personal care, people will spend more on textiles, people will spend more on painting their houses, pharmaceuticals, etcetera, etcetera. And that is why when I said in terms of our end market, we grow faster than the GDP. So there's a second element. We are supplying materials to good end markets, which will be growth drivers. Of course, it depends on us so that we are able to innovate well and so on and so forth and service our customers well.

36:03 And the third thing is that our innovation and our service of our customers will come from how good we are at spotting opportunities and delivering value to customers. For us, it comes from two or three things. I mentioned them before. It comes from our ability to deliver outstanding products, new functionalities, which we think we are good at. To leverage our sustainability credentials, and we are very eagerly looking at the next generation sustainable or performance chemicals as well. And third, so as to be able to deliver value not only within the country but outside, don't try and do everything yourself, be a great partner with many people. I think if we continue to get these things right and have the organization culture to get that right, that is what I will continue to focus Sometimes the pitch will be spinning more, sometimes it will be bouncing more, all that will be continued. But that is within my hands.

37:01 And given that, freight will come up, freight will go down, I can't predict that. But the more business is built on fundamentals, I think we will continue to find a place to grow our business profitably. Got it, sir. Thank you. Sir, if you could mention about our capital allocation strategy and how we are going to deal with the debt in the coming years? Regarding the debt, which has been allocated to India Glycols, the total long term debt allocated to India Glycol is INR $4.50 crores and which is repayable every year is about INR 125 crores.

37:48 So this is the long term debt, which we are having. And hopefully, we will be trying to reduce the debt, long term debt as early as possible. Relating to the working capital limit, yes, we have allocated the working capital limit out of the total limit which company was having. So now the India Glycol will be having about the working capital is a limit of INR 300 crores and some non fund base limit for the bank guarantees and the LCs. So that asset that is not much in the company when it is reduced. In the Capital Allocation, thanks, Sorry to interrupt, Mr. Balasubramanian. May I please request you to rejoin the queue, sir, for the follow-up question? Yes.

38:36 Okay, sir. Thank you. Next question is from the line of Saket Kapoor from Kapoor and Co. Please go ahead. Namaskar, are you people doing? We are all doing well. Hope you are doing well as well. Thank you, sir. Yes, sir.. Sir, firstly, if you could give the volume growth quarter on quarter, how have we moved from the June to the September quarter in terms of the volume growth? And we have seen the employee cost going down by 3 crores. Otherwise, the profitability would have taken a hit as being a similar employee expenses.

39:27 So just can you throw some light on the thing? Yes. Relating to the employee cost, which, Takaji, you have raised, actually what had happened is the cost has come down because of the reduction in the salary of the Chairman, which will be allocated into companies. So accordingly, the commission has also reduced. So earlier, we were doing more allocation and rest of the employee cost is continuing to be the same. Okay. So this number of 17 crore is now the number which will take on a quarterly basis? INR 17 crores and INR 17.5 crores in first quarter, there is some variable salary payment also, which is based So on the I hope that this will continue as it is INR 17 crores to INR 17.5 crores.

40:30 Okay. And on the volume growth factor? Yes. So you were talking about volume over the previous quarter, right? Yes, quarter on quarter, how has the volume been there? What kind of volume growth have you executed? So broadly speaking, our volume growth over same quarter last year is roughly about 10%, whereas value growth is about 35%. Second thing is compared to prior quarter, which is the quarter before the quarter that we are having the Board meeting for, the volume growth is roughly about 3%, value growth is higher. The last point I missed come again.

41:21 So I said the volume growth compared to previous quarter is 3% on an overall basis and value growth is higher than that, is about 9%, I think. Right. Correct, sir. And sir, now taking into account, think so the aspirational targets and stuff, which we have mentioned in the presentation, our capital work in progress, closing balances, I think, so at 114. So, sir, it is quite. And how is the MSU going to perform? If you could give us now what has been the contribution for the first half? And I think that the Performance Chemicals and NSU are the same nomenclature, sir?

42:10 Or are Yes, they combination of two things, right? So sustainable performance chemicals includes new performance chemicals and also materials that we sell to the joint venture, okay? The smaller is the performance chemicals business. And we are in terms of volume growth, that Performance Chemicals business compared to same quarter of last year has grown by about just one second, has grown by about 90%. And compared to previous quarter volume growth in that separate small division for which we do not separately now report as a detailed results is about 74%.

42:58 So we expect significant top line growth in the new Performance Chemicals business this year. Okay. So that is the NFU unit, I think, so wherein we have put some CapEx also some in the tune of 70 crore earlier. Saket, I am deliberately not calling it NSU because see, NSU is a physical access, new specialty unit. But what we will eventually work on is new chemicals that we are introducing. And the reason I'm saying so is very interestingly that we are also modifying some of our assets to make performance chemicals. For example, we are modifying one old glycol ethyl to make some mines, etcetera. So we will increasingly use the word new performance chemicals.

43:51 Okay. And now sir, on the capital work in progress, this INR 114 crore closing balance, what it is attributable to and how when are we going to capitalize? And second point, Anandji, is on the investment in the joint venture. I think that closing balance is also up to INR $4.22. So on the dividend and the proceeds part, can you just reiterate when are we going to receive the balance amount and this INR $4.22 number has why has the number gone up, sir? Not clear, but this much I can say that every year they are ready to pay the dividend and whatever discussion we have with KB, some of the dividend they will pay in the month of December and the final dividend will come in the March.

44:45 I'm not sure how much money will come in the shape of the dividend, but it will be around INR 50 to 60 crores. This is what I have got. Regarding this INR $4.22 crores which you are mentioning the investment in the JV, so that I have to see and I will come back to you. That's the CWIC sir. Pardon? CWIP 114, there are say about 14, 15 CapExes, which is going on, which Rupakji has already told regarding the capacity enhancement in the mine manufacturing and some other CapExes.

45:36 That is all on the completion stage. Some of the CapExes, which will be completed by June 27, while most of the CapExes will be completed by December, January 27. So as soon as all the CapExes are complete or completed, then certainly that will be capitalized as per the completion date. Correct, sir. And when we look last point is on the again on the presentation, I think so we aspire to do INR 200 crore of EBITDA for FY twenty twenty six, twenty seven that could be our that could be a fair understanding as we mentioned in Slide number 25? Yes. So H2 looks better than H1, sir. That is what the basic understanding should be.

46:24 Sorry? That you can decide yourself there, Prakash. Yes, sir. Yes, sir. No, sir. H1 we have did, we have done EBITDA of just a second, sir. H1 EBITDA number is closer to INR 180 crores, I think. Yes, 79 crores is the EBITDA we have done for the first half and INR 200 crores is what we are mentioning it for the full year. That understanding is correct. Just one thing I would like to add. When we look at the overall P and L, we and Anand, you can correct me. I think there is a disconnect here. We also add the JV bit of the correct. So INR 80 crores has already come in H1 and rest of the INR 120 crores which you are mentioning here to make it 200 crores H1... So without saving income it about 113 So 113 crores including JV, but I will talk only about India Glycols. So it is about INR 80 crores and whatever 200 crores we can target, the target is including the JV.

47:34 That is including the JV? It is very important, Saket, to understand that it is not as if we are an investor in the JV. JV is completely dependent on a unique material that we supply, which is bio based cysteine oxide. And the only way we get to see the returns of that bio based histamine oxide is through the dividend or through the JV. Otherwise, So in the right rationale also, that is how it should be viewed. Okay. And last point is on the ethoxylate part, sir. I think so availability of ethoxylate had been an issue earlier because of the geopolitical and thereby even the prices price maybe variations are. So how is currently the cost of your market currently placed in terms of favorability and the pricing?

48:32 So Saket, availability was not the issue, more than that price was the issue because crude prices went up and the lion prices obviously go up in line with the crude. The availability issue was largely around glycols, DEG, etcetera, some of which directly gets imported from The Middle East. I do not know in what quantities, etcetera. So the impact was more on price. In for a very short time, it also gave us some advantage in the market because the differential, which was generally in favor of Reliance's EO was kind of neutralized. I think right now, it is not as there is a differential, not very high, and it is very, very difficult to predict which way it is going.

49:23 But I think it is likely to continue at similar levels. And I don't see a big either a headwind or a tailwind happening because of this in the remaining part of the year. Sir, I'll join the queue for a follow-up. Sir, when you give the presentation going ahead also, sir, if we can also provide the key R and M mix in one of your slides, I might have missed it if you have mentioned. You just try to make an understand how the what are the key what is the basket of RM and how have RM behaves for the quarter end reporting? So that would give us We will include some commentary. Though briefly, we have ended up discussing most of them.

50:11 Our single biggest RM is ethanol, which we discussed and the silicon And then our RM other than that big RM is coal, which is for energy. And three other RMs, I named, I named properly oxide, laurel alcohol and phenol. So but significant Thank you, sir. To the team, I will listen to the call. Thank you, sir. I'll join the Yes. You. Next question is from the line of Satak Jain from Desvalado Advisory.

50:57 Go ahead. Evening. Am I audible? Yes. Please go ahead. Thanks for the opportunity. Sir, actually, in the August call, you had indicated an aspiration of generating over $1.50 crore revenue from the new specialty unit in FY '27 with a longer term ambition of INR 600 crores to INR 700 crores over four to five years. So sir, how has the unit performed in H1 FY 'twenty seven? Also, how much of the new product pipeline has moved into regular commercial orders? So let me tell you that we are doing well as per our plan. And even as per the aspirations indicated with I would expect to hopefully beat what we had mentioned, both in terms of the next few years aspirations as well as this year's aspirations. Again, that is what I can tell you right now. That's what we are hoping for.

52:00 Sir, if you can just give the utilization level, like what are you targeting over the next twelve to eighteen months? Utilization. The new specialty unit. Right now, in a new see, specialty units are not like a petrochemical plant, 80%, 90% occupancy. What happens is that there are multiple sets of equipment, some of which depending on requirements in certain areas, sometimes get bottlenecked. For example, we are bottlenecked in certain capacities. In some cases, we develop a product, suddenly there is good demand, but we have to jack up our capacities.

52:46 So I think ballpark, I will give you, it's very difficult to give a number. I think we are very healthy we have a very healthy occupancy of our new specialty unit. In some areas, actually, are running full. We are doing small debottlenecking investments to continue to get those volumes up. So that is how it is. As there are no further questions from the participants, I now hand the conference over to Mr.

53:45 Rupak Saraswat for the closing comments. Thank you very much, except that you were causing me some anxiety by repeatedly asking people to ask some more questions. Once the examination all you need not utilize all the time. That was on a lighter note. So no, no, I think it was a pleasure of mine to talk to you about this new business. And I hope we were able to give you some direction on how the business is doing, what we are doing. And thank you for your indulgence on behalf of my team here, and have a good evening. Thank you. Thank you very much, sir. On behalf of India Glycols Limited, that concludes this conference. Thank you all for joining us and you may now disconnect your lines.

Follow India Glycols Limited into a list and get an email when it puts out news.

Latest news releases

Companies on this call

Speakers

Rupak Saraswat

Chief Executive Officer at India Glycols Limited

Anand Sagal

Chief Financial Officer at India Glycols Limited

Ankur Jain

Head Legal and Company Secretary at India Glycols Limited

Saket Kapoor

at Kapoor and Co.

Satak Jain

at Desvalado Advisory

More from India Glycols Limited